GSK's secret vaccine adjuvant draws attention

GlaxoSmithKline's success advancing two pandemic vaccines--Prepandrix and Pandemrix--relies on a secret formula that drives efficacy of a low antigen dose in these adjuvated products. According to In Vivo, Glaxo has been careful to keep the proprietary adjuvant secret throughout the approval process. As Glaxo has noted, a pandemic would require massive quantities of vaccine for any effective campaign to protect populations--and adjuvants are considered a key to making sure that vaccine stocks can be spread far and wide enough to prevent an outbreak. At some point, In Vivo notes, Glaxo will have to either unveil the adjuvant to European or U.S. regulatory officials.

- read the feature in In Vivo

Related Articles:
GSK pre-pandemic vaccine shows promise. Report
GSK wins EMEA approval for pandemic vaccine. Report
HHS awards H5N1 contracts. Report

Suggested Articles

Novavax has inked a $60 million contract with the U.S. Department of Defense to help fund U.S.-based manufacturing of its COVID-19 vaccine candidate.

Since the Warp Speed selections went public, experts have been wondering why some drugmakers were left off.

A few years ago, one of our Fierce editors met a Big Pharma R&D chief for the first time. “You’re the ones with the scary name,” he joked.